{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["52"],"submitter":["Brooks BR"],"pubmed_abstract":["<h4>Background</h4>We aimed to evaluate overall survival in US patients with amyotrophic lateral sclerosis (ALS) treated with intravenous (IV) edaravone compared with those not treated with IV edaravone in a real-world setting.<h4>Methods</h4>This exploratory retrospective comparative effectiveness observational analysis included patients with ALS who were enrolled in an administrative claims database from 8 August 2017 to 31 March 2020. Propensity score matching identified IV edaravone-treated patients (cases) and non-edaravone-treated patients (controls) matched for covariates: age, race, geographic region, sex, pre-index disease duration, insurance, history of cardiovascular disease, riluzole prescription, gastrostomy tube placement, artificial nutrition, noninvasive ventilation, and al"],"journal":["EClinicalMedicine"],"pagination":["101590"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9358426"],"repository":["biostudies-literature"],"pubmed_title":["Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis."],"pmcid":["PMC9358426"],"pubmed_authors":["Liu Y","Zhang J","Hagan M","Brooks BR","Berry JD","Ciepielewska M","Zambrano GS"],"additional_accession":[]},"is_claimable":false,"name":"Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis.","description":"<h4>Background</h4>We aimed to evaluate overall survival in US patients with amyotrophic lateral sclerosis (ALS) treated with intravenous (IV) edaravone compared with those not treated with IV edaravone in a real-world setting.<h4>Methods</h4>This exploratory retrospective comparative effectiveness observational analysis included patients with ALS who were enrolled in an administrative claims database from 8 August 2017 to 31 March 2020. Propensity score matching identified IV edaravone-treated patients (cases) and non-edaravone-treated patients (controls) matched for covariates: age, race, geographic region, sex, pre-index disease duration, insurance, history of cardiovascular disease, riluzole prescription, gastrostomy tube placement, artificial nutrition, noninvasive ventilation, and al","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-04T19:27:43.829Z","creation":"2025-04-04T19:27:43.829Z"},"accession":"S-EPMC9358426","cross_references":{"pubmed":["35958519"],"doi":["10.1016/j.eclinm.2022.101590"]}}